Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
AssigneeMerus N.V.
InventorsErnesto Isaac WASSERMAN, Eduardo Jose PENNELLA
Life of this patent
Estimating the term…
Abstract
The disclosure relates to means and methods in the treatment of cancer. The disclosure in particular relates to a method of treating a cancer in an individual with an antibody that at least binds EGFR and an immune checkpoint inhibitor (ICI). The invention further relates to the use in such methods and to use in the manufacture of a medicament for the treatment of a cancer that has not been previously treated with a therapeutic agent having anti-cancer properties. Such a combination of said antibodies and an ICI are particularly useful in the treatment of cancers, such as head and neck cancer.
Claims37
An antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR for use in the treatment of a cancer in a subject, wherein the treatment further comprises administering an immune checkpoint inhibitor.
A method of treating cancer in a subject, the method comprising administering an effective amount of an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR and an effective amount of an immune checkpoint inhibitor to the subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the cancer is a cancer of the pharynx (including nasopharynx, oropharynx and hypopharynx), oral cavity, larynx, paranasal sinuses, nasal cavity or salivary glands.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein said immune checkpoint inhibitor comprises a PD-L1, PD-L2 or PD-1 inhibitor.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the immune checkpoint inhibitor is an antibody that binds PD-L1, PD-L2 or PD-1.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the immune checkpoint inhibitor is pembrolizumab.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein said subject has not received prior anti-cancer treatment for treatment of said cancer.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the subject is a mammal.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the subject is a human subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof, is a multispecific antibody.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof, is a bispecific antibody.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody that comprises a variable domain that binds an extracellular part of EGFR, is petosemtamab.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein said treatment comprises administration of a dose of 400 mg of pembrolizumab as immune check point inhibitor once every six weeks to the subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein petosemtamab as antibody that comprises a variable domain that binds an extracellular part of EGFR and pembrolizumab as immune checkpoint inhibitor are sequentially administered.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein if pembrolizumab as immune checkpoint inhibitor and petosemtamab as antibody that comprises a variable domain that binds an extracellular part of EGFR are administered on the same day, pembrolizumab is administered after petosemtamab.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof or the immune checkpoint inhibitor is provided intravenously to the subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof is ADCC enhanced.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof antibody is afucosylated.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the cancer is recurrent, unresectable, locally advanced and/or metastatic cancer.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the treatment comprises or is preceded by a step of diagnosing the subject or the cancer for PD-L1 expression.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the cancer has a Combined Positive Score (CPS) for PD-L1 expression of 1 or more, but not more than 100.
A kit of parts comprising an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR as defined in any one of the preceding claims, an immune checkpoint inhibitor as defined in any one of the preceding claims and instructions for use of said antibody or functional part, derivative and/or analogue thereof and for use of said immune checkpoint inhibitor.
Dependencies are inferred from the claim text.